Trofinetide

Trofinetide is a methylated, metabolically stabilized analog of glycine-proline-glutamate (GPE), the naturally occurring N-terminal tripeptide cleaved from insulin like growth factor 1. It was approved by the United States FDA on 10 March 2023 under the brand name Daybue for the treatment of Rett syndrome, becoming the first therapy ever approved for that rare neurodevelopmental disorder. Approval rested on a randomized phase 3 trial in females with Rett syndrome in which twice daily oral trofinetide produced statistically significant improvement over placebo on the Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression of Improvement, with diarrhea the most common treatment emergent adverse event.

Its precise mechanism is not fully established but is proposed to involve improved dendritic and synaptic architecture and modulation of neuroinflammation and glial function. Pharmacokinetic work shows it can be dosed without regard to food and is excreted largely unchanged in urine. Trofinetide is included here as a neurotrophic peptide analog of genuine clinical interest; it is a prescription drug for a specific pediatric indication and is not a general nootropic. It is also under investigation for related neurodevelopmental conditions such as Fragile X syndrome.

The most common adverse effects in trials were diarrhea and vomiting, mostly mild to moderate; diarrhea occurred in a large majority of treated patients. It is a prescription medicine that should be used under medical supervision, with attention to hydration and weight.

Trofinetide is not a meaningful cytochrome P450 substrate or inhibitor; its interactions run through drug transporters instead, which is unusual enough to be worth stating plainly.

BCRP inhibition is the one with real consequence. Trofinetide inhibits BCRP, so BCRP substrates such as rosuvastatin can reach higher plasma concentrations when the two are given together, raising the risk of statin-associated myopathy. Intestinal BCRP is the main site, so orally administered substrates are affected most.

Trofinetide also inhibits P-glycoprotein and, in vitro, OAT1, OCT2, OATP1B1, OATP1B3, MATE1 and MATE2-K. Most of these are not expected to produce clinically significant interactions at real-world exposures, but sensitive P-gp and CYP3A substrates with narrow margins, where a small rise in concentration can cause serious harm, are treated more cautiously. Inhibition of BSEP in vitro is a theoretical cholestasis signal rather than a documented clinical event.

Checking a whole stack? Run it through interactions + stacks.

First disclosed by Neuren Pharmaceuticals around 2000 as a GPE analog, later co developed with Acadia Pharmaceuticals and approved for Rett syndrome in 2023.

Recognized as a landmark first in class approval for Rett syndrome; viewed clinically as meaningful but modest in effect size and notable for gastrointestinal tolerability issues.